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ABSTRACT 
Background: Topical corticosteroids have long been the cornerstone in the 
treatment ofsteroid-responsive dermatoses. Despite the effectiveness of these formu- 
lations, there is a misperception that drugs delivered via ointments are more po- 
tent han those delivered via other vehicles. Potency, however, is a complex function 
of the physical and chemical properties of both the active ingredient and its ve- 
hicle. Studies have determined that newer vehicles (eg, lotions), particularly those 
in the super-high-potency class, not only heighten the ability of the active ingredient 
to penetrate skin but also are preferred by patients over ointments and creams. 
Objective: This review of the literature investigates the effectiveness and 
tolerability of a high-potency corticosteroid lotion compared with cream or 
emollient cream formulations in treating moderate to severe plaque-type psori- 
asis and atopic dermatitis. 
Methods: A literature search was conducted of US and international published 
clinical trials (1975 to November 2004) comparing all potencies of topical corti- 
costeroid cream and lotion formulations using MEDLINE and the Web sites 
of individual dermatologic journals. No specific study designs were excluded 
from this search. Search terms included corticosteroid-responsive dermatoses, 
creams versus lotions, topical corticosteroid clinical trials, plaque-type psoriasis, 
atopic dermatitis, clobetasol propionate, drug bioavailability, Class I topical agents, 
and vasoconstriction. The primary diagnoses were moderate to severe plaque-type 
psoriasis and atopic dermatitis. Two unpublished clinical investigations compar- 
ing clobetasol propionate lotion 0.05% with clobetasol propionate cream 0.05% 
and emollient cream 0.05% in a total of 421 patients were also included. 
Results: In the 20 published and 2 unpublished trials identified and reviewed, 
the response rates were comparable between the lotion and cream formulations. 
In addition, in a psoriasis tudy, clobetasol lotion received significantly better 
cosmetic-acceptability ratings compared with clobetasol cream (P < 0.05). 
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Conclusion: In the studies reviewed, the effectiveness and tolerability of clo- 
betasol lotion were comparable to those of clobetasol cream and emollient cream 
in studies in adults with moderate to severe psoriasis or atopic dermatitis. (Curt 
Ther Res Clin Exp. 2005;66:154-171) Copyright © 2005 Excerpta Medica, Inc. 
Key words: topical corticosteroids, potency, vehicle, vasoconstriction, anti- 
inflammatory, clobetasol propionate, Class I agents, plaque-type psoriasis, atopic 
dermatitis, efficacy, safety, duration of response, cosmetic acceptability. 
INTRODUCTION 
Clinical Applications of Topical Corticosteroid Creams and Lotions 
Factors considered when selecting a topical corticosteroid for the treatment 
of psoriasis or atopic dermatitis include body site, disease state, drug concen- 
tration, method of application, and vehicle appropriateness. 1 The contribution 
of the vehicle to the bioavailability and potency of topical corticosteroid prepa- 
rations was not fully appreciated until the mid-1970s. 1 Today the importance of 
an optimal vehicle in maximizing drug bioavailability is recognized. In addition, 
dose-response tudies can be used to determine the maximum effective concen- 
tration associated with a given vehicle. 1
A common misperception is that topical corticosteroid ointments are inher- 
ently more potent than other vehicle formulations because of increased rug 
penetration. However, although ointments moisturize dry psoriatic plaques, 
they are not necessarily more potent than other vehicles. In fact, potency is a 
complex function of several factors: the bioavailability of the active ingredient, 
chemical and physical stability of the vehicle to optimally deliver the active 
ingredient, area and state of diseased skin, and duration of use. 1-4 
The activity of a given topical agent can be enhanced by vehicle changes that 
result in the delivery of more drug. These changes often involve adding dimethyl 
sulfoxide, dimethylacetamide, N-methylpyrrolidine, urea, and propylene glycol, 2 
penetration enhancers that increase the reservoir of corticosteroid in the stra- 
tum corneum. Although the mechanism of action of penetration enhancers i not 
well understood, these agents heighten the therapeutic activity of a topical for- 
mulation by (1) hydrating the stratum corneum to facilitate passage of the drug; 
(2) enhancing the thermodynamic a tivity of the active ingredient, increasing its 
ability to penetrate viable tissue; and (3) transiently increasing epidermal intra- 
cellular gaps that allow greater passive diffusion of the drug. 
Because the vasoconstrictive activity of a corticosteroid generally correlates 
with its anti-inflammatory potency, vasoconstrictor assays can be used to pre- 
dict the clinical activity of a given corticosteroid. Vasoconstriction scores are 
used to rank corticosteroids according to their potency. Class I agents are con- 
sidered super-high-potency topical corticosteroids (Table 1). 3,4 
The potency of a topical corticosteroid, in addition to its drug concentration 
and/or duration of exposure, determines the intensity of vasoconstriction. 5,6 
The more potent he topical corticosteroid, the earlier the maximal effect is ob- 
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Table I. Class I corticosteroids: super-high-potency topical corticosteroids. 3,4 
Generic Name Trade Name 
Betamethasone dipr0pionate 
CIobetasol propionate 
Diflorasone diacetate 
Halobetasol propionate 
Diprolene ®* ointment, gel, lotion, 0.05% 
Clobex ®* lotion, 0.05%; Olux ®~ foam 0.05%; 
Temovate ®§ cream, ointment, gel 0.05%; 
Temovate E ®§ emollient 0.05% 
Psorcon E ®11 emollient ointment 0.05% 
Ultravate ®q] cream, ointment 0.05% 
*Schering-PIough Corporation, Kenilworth, New Jersey. 
tGalderma Laboratories, LP, Fort Worth, Texas. 
~Connetics Corporation, Palo Alto, California. 
§GlaxoSmithKline, Research Triangle Park, North Carolina. 
IIDermik Laboratories, Berwyn, Pennsylvania. 
qlBristoI-Myers Squibb Company, Princeton, New Jersey. 
served. 6 Thus, with a super-high-potency topical corticosteroid (eg, clobetasol 
propionate), topical exposure for a short time (eg, 1 hour) results in a vasocon- 
strictive response similar to that with exposures of as long as 16 hours. 5Use of 
the super-high-potency agents on the face, groin, or axillae is contraindicated. 
Treatment should be limited to a maximum of 2 consecutive weeks, with ~2 ad- 
ditional weeks for localized lesions. 
Impact  of  Vehicle Techno logy  on Skin Penet ra t ion  
Advances in vehicle technology have allowed enhanced istribution of topE- 
cal corticosteroids, as illustrated by the results of an in vitro trial comparing 
the amount of drug recovered after the application of 0.05% clobetasol propi- 
onate lotion,* cream,~ or emollient c reams Skin obtained by surgical excision 
was treated and stored. Levels of clobetasol were measured after centrifugation 
and extraction of the skin sample. Significantly more clobetasol was recovered 
in the epidermis (including the stratum corneum) with the lotion compared 
with the cream (P = 0.013) (Table If). 7 Likewise, significantly more drug was 
recovered from the epidermis and dermis with the lotion compared with the 
emollient cream (P < 0.001). 
Target  Disease States 
The super-high-potency agents are used for treating dermatoses that are 
mildly or moderately responsive to topical corticosteroids (Table 110. 3 Class I 
agents are used for treating significant inflammation or skin that is so thick 
(either inherently or as the result of disease) that penetration would likely be 
poor. Typical indications for Class I agents include plaque psoriasis of the body, 
*Trademark: CIobex ® (Galderma Laboratories, LP, Fort Worth, Texas). 
tTrademark: Temovate ® (GlaxoSmithKline, Research Triangle Park, North Carolina). 
~Trademark: Temovate E ® (GlaxoSmithKline). 
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Table II. Cutaneous penetration of clobetasol propionate in vitro, as measured by 
percentage of applied clobetasol dose recovered. 7 
Lotion Cream Emollient Cream 
Skin Layer 0.05% 0.05% 0.05% 
Epidermis* 10~ 
Dermis 2~ 3 0.1 
Dermis + epidermis 
(total cutaneous 
penetration) 12 8 5 
*Including stratum corneum. 
tp = 0.01 3 versus cream. 
~P < 0.001 versus emollient cream. 
Table III. Responsiveness of selected dermatoses to topical 
corticosteroids. 
Highly responsive 
Psoriasis (intertriginous) 
Atopic dermatitis (children) 
Seborrheic dermatitis 
Intertrigo 
Moderately responsive 
Psoriasis (body) 
Atopic dermatitis (adults) 
Nummular eczema 
Parapsoriasis 
Lichen simplex chronicus 
Primary irritant dermatitis 
Papular urticaria 
Least responsive 
Palmoplantar psoriasis 
Psoriasis of nails 
Lichen planus 
Lupus erythematosus 
Allergic contact dermatitis, acute phase 
Dyshidrotic eczema 
Pemphigus 
Granuloma annulare 
Necrobiosis lipoidica diabeticorum 
Sarcoidosis 
Insect bites 
Adapted with permission. 3
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palmoplantar psoriasis, lichen planus, lichen simplex chronicus, lupus erythe- 
matosus, and acute exacerbations of atopic dermatitis in adults. 3
Psoriasis, not including psoriasis of the nails, is the most common dermatosis 
for which the Class I topical corticosteroids are prescribed. 
COMPARISON OF CREAM AND LOTION FORMULATIONS OF 
TOPICAL CORTICOSTEROIDS 
In November 2004, a literature search of US and international published clinical tri- 
als was conducted using MEDLINE and Web sites of individual dermatologic jour- 
nals for the period 1975 to November 2004. Search terms included corticosteroid- 
responsive dermatoses, creams versus lotions, topical corticosteroid clinical trials, 
plaque-type psoriasis, atopic dermatitis, clobetasol propionate, drug bioavailability, 
Class I topical agents, and vasoconstriction. 
The objective of this review was to investigate the effectiveness and tol- 
erability of topical corticosteroid creams and lotions. Primary diagnoses 
were psoriasis and atopic dermatitis. Twenty investigations that included 
cream and/or lotion treatment arms were identified. 8-27 Only 1 published 
study compared Class I corticosteroid lotion and creams. 8 Two unpublished 
comparative trials of Class I lotions and creams are also presented in this 
review. 28,29 One study evaluated 229 patients with atopic dermatitis. The 
results were presented at the annual meetings of the World Congress of 
Dermatology (2002) and European Academy of Dermatology and Venere- 
ology (2003). 28 The second, unpublished investigation i volved 192 patients 
with psoriasis who were also treated with a Class I lotion or cream. 29 The 
identified studies are presented in Tables IV to VI. Two psoriasis tudies 8,29 
and 1 atopic dermatitis tudy 28 involving lotions were identified. Although a 
variety of study designs were used, a review of the results revealed no evi- 
dence that topical corticosteroid cream formulations are inherently more 
potent han lotion formulations. 
No notable differences were found in the overall treatment response rates 
for creams and lotions, regardless of the potency of the corticosteroid. In
both psoriasis and atopic dermatitis, high response rates were achieved with 
Class I agents. 
Patient Preference 
In the United States, more than 1 million in 4.5 million patients diagnosed 
with psoriasis report substantial dissatisfaction with their treatment, even if 
skin involvement is not extensive. 3°According to the results of 2 patient pref- 
erence studies in which this author participated, much of this dissatisfac- 
tion may be attributable to the vehicle used to deliver therapyY ,32 In these 
2 studies, based on a 7-parameter p eference measure, patients indicated apref- 
erence for "less messy" foam and solution vehicles compared with cream, gel, 
and ointment vehicles (all, P < 0.01). 31 In addition, in another study, patients 
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Table VI. Overall rates of response (%) to topical corticosteroid creams versus lotions 
in published clinical trials. 8-2z 
Psoriasis Atopic Dermatitis 
Corticosteroid 
Potency Cream Lotion Cream Lotion 
All potencies 25-88 47-74 70-97 88 
Non-Class I 43-88 47-72 70-97 88 
Class I 62-88 74 88-93 N/A 
reported a preference for corticosteroid lotions over creams in each of the fol- 
lowing aspects: "satisfactory penetration time" (P = 0.043), "dries quickly" (P = 
0.002), "greasy sensation" (P = 0.001), "pleasing aspect" (P = 0.001), "pleasing 
perfume" (P = 0.001), and "film on the skin" (P = 0.017). 8In a fourth study, 33 39% 
of patients with psoriasis indicated being noncompliant with therapy due to its 
"messiness" and "time-consuming ature"33; thus, further investigation may 
find that vehicle preferences significantly impact patient compliance. 32Such 
preferences could explain greater clinical improvement in patients with atopic 
dermatitis treated with topical corticosteroid cream compared with ointment. 34
In 1 of these studies, patients with plaque-type psoriasis rated the cosmetic 
acceptability of clobetasol lotion higher compared with that of clobetasol 
cream. 8 This increased acceptability of the lotion might improve treatment 
compliance, which, in turn, might enhance patient outcomes. 
Direct Comparison of  the Effectiveness of  Lotion Versus Cream 
Formulations of  a Class I Corticosteroid: Results of 3 Clinical Studies 
Psoriasis Studies 
Two multicenter, andomized, active- and vehicle-controlled studies (1 pub- 
lished 8and 1 unpublished 29) compared clobetasol propionate lotion 0.05% with 
vehicle (control group) and with equal-strength formulations of clobetasol in a 
cream or emollient cream vehicle. Both studies included predominantly white 
male and female patients aged >18 years with moderate to severe plaque-type 
psoriasis involving at least 10% body surface area and with a total baseline derma- 
tologic sum score (DSS) (scale: 0 = none to 4 = severe [for each sign of psoriasis]) 
->6 on the target area. 
Psoriasis Study 1 
In the first study, 222 patients applied clobetasol propionate lotion 0.05% (n = 
94), clobetasol propionate cream 0.05% (n = 95), or lotion vehicle (control 
group) (n = 33) to the affected areas BID for 4 weeks. Patients were evaluated at 
baseline and at days 7, 14, and 28. 8 
Efficacy evaluations included a 6-point global severity score (GSS) (scale: 0, 
0.5, 1.0 = success; 2, 3, 4 = failure); individual signs of erythema, plaque eleva- 
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tion, and scaling (each assessed on a 5-point Likert scale: 0 = none to 4 = very 
severe); a DSS (defined as the sum of severity scores for erythema, plaque ele- 
vation, and scaling; range, 0-12); a 5-point global improvement score (scale: 1 = 
worse to 5 = clear); and the percentage of body surface area involved. 
The DSS and GSS scores were significantly lower with clobetasol lotion 0.05% 
compared with the lotion vehicle (both, P < 0.001). In addition, no significant dif- 
ferences in mean DSS or GSS were found between clobetasol lotion 0.05% and 
clobetasol cream 0.05% at any visit (Figure 1). 8 
Reductions in the DSS at the end of treatment were 81% with clobetasol 
propionate lotion 0.05% and 85% with clobetasol propionate cream 0.05%. The 
mean GSS at baseline, which was 2.6 in all 4 treatment groups, was decreased 
to 0.7 in the lotion group, to 0.6 in the cream group, and to 1.9 in the control 
group. At the end of treatment, 76% of patients who used clobetasol lotion and 
77% of those who used clobetasol cream rated global improvement as 3 or 4 
(almost clear/clear) compared with 9% of those who used the lotion vehicle 
(both, P < 0.001). 8 Treatment-related a verse events occurred in 2 patients 
treated with clobetasol lotion, in 2 patients treated with clobetasol cream, and 
in none of the patients treated with the lotion vehicle. No clinically significant 
local skin reactions were found with any of the study medications. 
Compared with clobetasol cream, clobetasol lotion received significantly bet- 
ter ratings on 6 measures of cosmetic acceptability ("satisfactory penetration 
time," "dries quickly," greasy sensation," "pleasing aspect," pleasing perfume," 
and "film on the skin") (all, P < 0.05) (Figure 2). 8 
Psoriasis Study 2 
In the second study, 29 192 patients applied clobetasol propionate lotion 0.05% 
(n = 82), emollient cream 0.05% (n = 81), or lotion vehicle (control group) 
(n = 29) to the affected areas BID for 4 weeks. The primary end point was the 
success rate derived from the GSS (0 = best response to 4 = worst response). 
Treatment success was a GSS of 0, 0.5, or 1 (clear, almost clear, or mild overall 
severity, respectively [ie, success]), and failure was a GSS of 2, 3, or 4. 
At the end of therapy, the mean GSS in the group receiving clobetasol 
lotion 0.05% was statistically similar to that of the group receiving clobetasol 
propionate 0.05% emollient cream and significantly lower compared with the 
control group (P< 0.001). Success rates were 41%, 37%, and 0% in the groups 
receiving the emollient cream, lotion, and vehicle, respectively. A total of 77% 
of patients treated with clobetasol lotion maintained success at the 4-week 
follow-up visit compared with 49% of those treated with clobetasol emollient 
cream (Figure 3). 29 
Treatment-related adverse vents occurred in 5 patients treated with clobe- 
tasol lotion, 2 treated with clobetasol emollient cream, and 3 treated with 
lotion vehicle. One patient receiving clobetasol emollient cream discontinued 
treatment due to an adverse vent (irritant contact dermatitis). Other adverse 
events included atrophy, telangiectasia, skin discomfort, and dryness. 
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[] Clobetasol propionate lotion 
[] Clobetasol propionate cream 
[] Vehicle 
A 
e~ 
e- 
I I I i 
Baseline Day 7 Day 14 Day 28 
m
B 
e- 
3° 1 
2.5- 
2.0- 
1.5- 
1.0- 
0.5  - 
0-  I I I 
Baseline Day 7 Day 14 Day 28 
Figure 1. Effects of treatment with clobetasol propionate lotion 0.05%, cream 0.05%, 
or vehicle (control) on (A) dermatologic sum score (DSS) and (B) global 
severity score (GSS) (intent-to-treat population last observation carried for- 
ward). 8 DSS scale: sum of severity scores for erythema, plaque elevation, 
and scaling; range, 0-12. GSS scale: 0, 0.5, 1.0 = success; 2, 3, 4 = failure. 
*P < 0.001 versus vehicle. 
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• Clobetasol propionate lotion 
[] Clobetasol propionate mollient cream 
80- 
v 
e, ,  
o,1 
70- 
60- 
50- 
40- 
30- 
20- 
10- 
0 l/ I - -1  
End of Treatment 4-Week Follow-Up 
Figure 3. Comparison of rates of treatment success with clobetasol lotion 0.05% and 
emoliient cream 0.05% at the end of treatment and at 4-week follow-up. 29 
Summary of Psoriasis Studies 
In the 2 studies discussed previously, the effectiveness and tolerabil ity of 
clobetasol propionate lotion 0.05% were found to be similar to those of equal- 
strength formulations of clobetasol propionate cream 0.05% or emollient cream 
in the treatment of moderate to severe plaque-type psoriasis. 8,29 However, com- 
pared with clobetasol cream, clobetasol otion received significantly better 
ratings on 6 measures of cosmetic acceptabil ity (all, P < 0.05). 8 Corticosteroid- 
related local skin reactions (ie, telangiectasia and skin atrophy) were not reported 
with short-term treatment with clobetasol propionate lotion in these studies. 
Atopic Dermatitis Study 
A total of 229 male and female patients aged _>12 years with moderate to severe 
atopic dermatitis involving at least 20% of total body surface area and with a total 
baseline DSS at the target area of __.6 were enrolled in this unpublished trial. 28 
Patients applied clobetasol propionate lotion 0.05% (n -- 96), clobetasol propionate 
emollient cream 0.05% (n = 100), or lotion vehicle (control group) (n = 33) to the 
affected areas BID for 2 weeks and were followed up for an additional 2weeks after 
treatment. Patients were evaluated at baseline and at days 7, 14, and 28. 
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Efficacy evaluations included GSS and global improvement score, as de- 
scribed in the studies in patients with psoriasis. 8,29 The DSS was the sum of 
severity scores for erythema, excoriation, and induration/papulation; pruritus 
was assessed separately on a 5-point Likert scale (0 = none to 4 = very severe). 28 
The percentage of body surface area involvement also was assessed. The primary 
end point was the success rate based on reduction from baseline in the GSS. 
The GSS score was significantly lower with clobetasol propionate lotion 0.05% 
compared with vehicle (P = 0.001). Also, the success rates in the groups receiv- 
ing clobetasol propionate lotion 0.05% and clobetasol propionate mollient 
cream 0.05% were statistically similar at day 14 (Figure 4). 28 
The incidences of adverse effects were comparable between all 3 treat- 
ment groups; no clinically significant local skin reactions (ie, telangiectasia, 
skin atrophy) were observed with any of the study medications. Treatment- 
related adverse vents occurred in 4 patients treated with clobetasol lotion, 
1 patient reated with clobetasol emollient cream, and 6 patients who received 
the lotion vehicle. 
Summary of the Atopic Dermatitis Study 
The effectiveness and tolerability of clobetasol propionate lotion 0.05% were 
similar to those of clobetasol propionate mollient cream 0.05% in the treat- 
ment of moderate to severe atopic dermatitis. 28Corticosteroid-related local 
skin reactions were not observed with short-term treatment with clobetasol 
propionate lotion in this study. 
DISCUSSION 
Advances in vehicle technology have led to the development of new topical cor- 
ticosteroid preparations that are less greasy, easier to apply, penetrate the skin 
more rapidly, and are more cosmetically acceptable compared with traditional 
creams, gels, and ointments. 
Although only 1 direct comparison of Class I corticosteroid creams and 
lotions was found in the published literature, 8 these formulations achieved sim- 
ilar rates of clinical response in psoriasis 29 and atopic dermatitis 28in unpub- 
lished reports. In addition, patients with psoriasis have reported substantial 
dissatisfaction with cream, gel, and ointment vehicles and, in fact, generally pre- 
fer vehicles that are less messy or more patient friendly. 32 
Large, multicenter, andomized, controlled trials comparing clobetasol pro- 
pionate lotion 0.05% and its vehicle with clobetasol propionate 0.05% cream 
and emollient cream in patients with moderate to severe plaque-type pso- 
riasis 8,29 or moderate to severe atopic dermatitis 28found that the lotion was 
more effective compared with the lotion vehicle (control) and similarly or 
more effective than clobetasol propionate 0.05% cream and emollient cream. 
No clinically significant local skin reactions or adverse vents were observed 
with any of the study medications. 
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Figure 4. Effects of t reatment  with clobetasol propionate lot ion 0.05% or emol l ient  
cream 0.05% on (A) success rate, (B) dermatologic  sum score (DSS), and 
(C) global severity score (GSS) ( intent-to-treat populat ion last observation 
carried forward).  28 DSS scale: sum of severity scores for erythema, excoria- 
tion, indurat ion/papulat ion, and scaling; range, 0-12. Pruritus was assessed 
separately on a 5-point  Likert scale (0 = none to 4 = very severe). *P = 0.001 
clobetasol lotion versus vehicle. 
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CONCLUSIONS 
The vehicle chosen to deliver topical cort icosteroid t reatment  has long been 
recognized as an important  aspect  of the effectiveness of this therapy for pso- 
riasis and atopic dermatit is.  Based on the findings of the present review, pa- 
t ients prefer less messy  vehicles, such as lotions, to traditional creams, gels, 
and ointments.  Further studies are needed to compare  lotions with creams and 
to establ ish the impact of the vehicle on t reatment  compl iance. The effective- 
ness and tolerabil ity of c |obetasol  propionate lotion were similar to those of 
c lobetasol  cream and emoll ient cream in the 3 studies in pat ients with moder-  
ate to severe psor iasis or atopic dermatit is.  
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